NASDAQ: NLSP
Nls Pharmaceutics Ltd Earnings Dates, Reports, Calls

Nls Pharmaceutics earnings were -$9.3M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest NLSP earnings report on Jun 30, 2025 announced Q2 2025 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NLSP reported annual earnings of -$7.2M, with 120.5% growth.

NLSP earnings history

Current Revenue
$0.0
Current Earnings
-$9.3M
Current Profit Margin
0%

NLSP Return on Equity

Current Company
N/A
Current Industry
-10.1%
Current Market
30.7%

NLSP undefined

Current Company
-337.5%
Current Industry
-0.2%
NLSP is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NLSP announces earnings.

NLSP undefined

Current Company
0%
Current Industry
6.4%

NLSP vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NLSP-$7.05M-$9.34MN/A-$0.82
AIM-$14.93M-$16.17MN/A-$24.68
TCRT-$3.99M-$3.99MN/A-$2.46
ALZN-$6.17M-$6.89MN/A-$8.61
VIVS-$1.17M-$1.99MN/A-$0.20

Nls Pharmaceutics Earnings Reports & History FAQ

What were Nls Pharmaceutics's earnings last quarter?

Nls Pharmaceutics (NASDAQ: NLSP) reported Q2 2025 earnings per share (EPS) of N/A, up N/A year over year. Total NLSP earnings for the quarter were N/A. In the same quarter last year, Nls Pharmaceutics's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Nls Pharmaceutics stock.

Is Nls Pharmaceutics profitable or losing money?

As of the last Nls Pharmaceutics earnings report, Nls Pharmaceutics is currently losing money. Nls Pharmaceutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$7.36 million, a 417.1% decrease year over year.

What was NLSP's earnings growth in the past year?

As of Nls Pharmaceutics's earnings date in Q4 2025, Nls Pharmaceutics's earnings has grown year over year. NLSP earnings in the past year totalled -$9.34 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.